These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36615698)

  • 1. A Comparison of Primary Human Hepatocytes and Hepatoma Cell Lines to Model the Effects of Fatty Acids, Fructose and Glucose on Liver Cell Lipid Accumulation.
    Huggett ZJ; Smith A; De Vivo N; Gomez D; Jethwa P; Brameld JM; Bennett A; Salter AM
    Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of lipid metabolism in a novel immortalized human hepatocyte cell line.
    Green CJ; Johnson D; Amin HD; Sivathondan P; Silva MA; Wang LM; Stevanato L; McNeil CA; Miljan EA; Sinden JD; Morten KJ; Hodson L
    Am J Physiol Endocrinol Metab; 2015 Sep; 309(6):E511-22. PubMed ID: 26126685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploratory Data Analysis of Cell and Mitochondrial High-Fat, High-Sugar Toxicity on Human HepG2 Cells.
    Amorim R; Simões ICM; Veloso C; Carvalho A; Simões RF; Pereira FB; Thiel T; Normann A; Morais C; Jurado AS; Wieckowski MR; Teixeira J; Oliveira PJ
    Nutrients; 2021 May; 13(5):. PubMed ID: 34069635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomechanics of cultured hepatic cells during different steatogenic hits.
    Baldini F; Bartolozzi A; Ardito M; Voci A; Portincasa P; Vassalli M; Vergani L
    J Mech Behav Biomed Mater; 2019 Sep; 97():296-305. PubMed ID: 31151002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential capability of metabolic substrates to promote hepatocellular lipid accumulation.
    Hoang NA; Richter F; Schubert M; Lorkowski S; Klotz LO; Steinbrenner H
    Eur J Nutr; 2019 Dec; 58(8):3023-3034. PubMed ID: 30368556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucose and fatty acid metabolism in McA-RH7777 hepatoma cells vs. rat primary hepatocytes: responsiveness to nutrient availability.
    Hansson PK; Asztély AK; Clapham JC; Schreyer SA
    Biochim Biophys Acta; 2004 Aug; 1684(1-3):54-62. PubMed ID: 15450210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of fructose and 3,5-diiodothyronine (3,5-T(2)) on lipid accumulation and insulin signalling in non-alcoholic fatty liver disease (NAFLD)-like rat primary hepatocytes.
    Gnocchi D; Massimi M; Alisi A; Incerpi S; Bruscalupi G
    Horm Metab Res; 2014 May; 46(5):333-40. PubMed ID: 24816759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gryllus bimaculatus De Geer hydrolysates alleviate lipid accumulation, inflammation, and endoplasmic reticulum stress in palmitic acid-treated human hepatoma G2 cells.
    Kim N; Jung S; Lee E; Jo EB; Yoon S; Jeong Y
    J Ethnopharmacol; 2022 Jun; 291():115117. PubMed ID: 35182670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in glycolytic capacity and hypoxia tolerance between hepatoma cells and hepatocytes.
    Hugo-Wissemann D; Anundi I; Lauchart W; Viebahn R; de Groot H
    Hepatology; 1991 Feb; 13(2):297-303. PubMed ID: 1847350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemerin causes lipid metabolic imbalance and induces passive lipid accumulation in human hepatoma cell line via the receptor GPR1.
    Zhu L; Huang J; Wang Y; Yang Z; Chen X
    Life Sci; 2021 Aug; 278():119530. PubMed ID: 33887347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactive oxygen species-induced TXNIP drives fructose-mediated hepatic inflammation and lipid accumulation through NLRP3 inflammasome activation.
    Zhang X; Zhang JH; Chen XY; Hu QH; Wang MX; Jin R; Zhang QY; Wang W; Wang R; Kang LL; Li JS; Li M; Pan Y; Huang JJ; Kong LD
    Antioxid Redox Signal; 2015 Apr; 22(10):848-70. PubMed ID: 25602171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin signaling and glucose metabolism in different hepatoma cell lines deviate from hepatocyte physiology toward a convergent aberrant phenotype.
    Molinaro A; Becattini B; Solinas G
    Sci Rep; 2020 Jul; 10(1):12031. PubMed ID: 32694512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid and glucose metabolism in hepatocyte cell lines and primary mouse hepatocytes: a comprehensive resource for in vitro studies of hepatic metabolism.
    Nagarajan SR; Paul-Heng M; Krycer JR; Fazakerley DJ; Sharland AF; Hoy AJ
    Am J Physiol Endocrinol Metab; 2019 Apr; 316(4):E578-E589. PubMed ID: 30694691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomics of lipid-laden human hepatocyte cultures enables drug target screening for the treatment of non-alcoholic fatty liver disease.
    Breher-Esch S; Sahini N; Trincone A; Wallstab C; Borlak J
    BMC Med Genomics; 2018 Dec; 11(1):111. PubMed ID: 30547786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models.
    Zhang Y; Meng T; Zuo L; Bei Y; Zhang Q; Su Z; Huang Y; Pang J; Xiang Q; Yang H
    Mar Drugs; 2017 Jun; 15(6):. PubMed ID: 28587208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose transporter 8 (GLUT8) mediates fructose-induced de novo lipogenesis and macrosteatosis.
    DeBosch BJ; Chen Z; Saben JL; Finck BN; Moley KH
    J Biol Chem; 2014 Apr; 289(16):10989-10998. PubMed ID: 24519932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Sweet Connection? Fructose's Role in Hepatocellular Carcinoma.
    Dewdney B; Roberts A; Qiao L; George J; Hebbard L
    Biomolecules; 2020 Mar; 10(4):. PubMed ID: 32218179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of caveolin-1 in hepatocellular carcinoma arising from non-alcoholic fatty liver disease.
    Takeda M; Sakaguchi T; Hiraide T; Shibasaki Y; Morita Y; Kikuchi H; Ikegami K; Setou M; Konno H; Takeuchi H
    Cancer Sci; 2018 Aug; 109(8):2401-2411. PubMed ID: 29896915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modifying nutritional substrates induces macrovesicular lipid droplet accumulation and metabolic alterations in a cellular model of hepatic steatosis.
    Gunn PJ; Pramfalk C; Millar V; Cornfield T; Hutchinson M; Johnson EM; Nagarajan SR; Troncoso-Rey P; Mithen RF; Pinnick KE; Traka MH; Green CJ; Hodson L
    Physiol Rep; 2020 Jul; 8(13):e14482. PubMed ID: 32643289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An effective protocol for pharmacological defatting of primary human hepatocytes which is non-toxic to cholangiocytes or intrahepatic endothelial cells.
    Boteon YL; Wallace L; Boteon APCS; Mirza DF; Mergental H; Bhogal RH; Afford S
    PLoS One; 2018; 13(7):e0201419. PubMed ID: 30044872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.